UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Nature medicine, 2020-11, Vol.26 (11), p.1733-1741

2020

Volltextzugriff (PDF)

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

PloS one, 2017-08, Vol.12 (8), p.e0182665-e0182665

2017

Volltextzugriff (PDF)

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

Diagnostic pathology, 2016-10, Vol.11 (1), p.95-95, Article 95

2016

Volltextzugriff (PDF)

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation

Journal for immunotherapy of cancer, 2016-11, Vol.4 (1), p.76-76, Article 76

2016

Volltextzugriff (PDF)

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial

Liver cancer (Basel ), 2021-06, Vol.10 (3), p.249-259

2021

Volltextzugriff (PDF)

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations

Journal for Immunotherapy of Cancer, 2016-11, Vol.4 (1), p.77-77, Article 77

2016

Volltextzugriff (PDF)

Use of human tissue to assess the oncogenic activity of melanoma-associated mutations

Nature genetics, 2005-07, Vol.37 (7), p.745-749

2005

Volltextzugriff (PDF)

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2019-03, Vol.380 (12), p.1103-1115

2019

Volltextzugriff (PDF)

HLA-A03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study

The lancet oncology, 2022-01, Vol.23 (1), p.172-184

2022

Volltextzugriff (PDF)

Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort

European journal of cancer (1990), 2019-03, Vol.109, p.154-161

2019

Volltextzugriff (PDF)

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

Clinical cancer research, 2022-02, Vol.28 (4), p.738-747

2022

Volltextzugriff (PDF)

Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma

Cancer discovery, 2024-03, Vol.14 (3), p.406-423

2024

Volltextzugriff (PDF)

Hallmarks of Resistance to Immune-Checkpoint Inhibitors

Cancer immunology research, 2022-04, Vol.10 (4), p.372-383

2022

Volltextzugriff (PDF)

Consistent, Persistent Expression from Modified Retroviral Vectors in Murine Hematopoietic Stem Cells

Proceedings of the National Academy of Sciences - PNAS, 1998-08, Vol.95 (17), p.10182-10187

1998

Volltextzugriff (PDF)

In vivo Restoration of Laminin 5 β3 Expression and Function in Junctional Epidermolysis Bullosa

Proceedings of the National Academy of Sciences - PNAS, 2001-04, Vol.98 (9), p.5193-5198

2001

Volltextzugriff (PDF)

Use of TMB and PD-L1 to predict outcomes of checkpoint inhibitor treatment

Journal of clinical oncology, 2019-03, Vol.37 (8_suppl), p.150-150

2019

Volltextzugriff (PDF)

Sustainable systemic delivery via a single injection of lentivirus into human skin tissue

Human gene therapy, 2001-08, Vol.12 (12), p.1551-1558

2001

Volltextzugriff (PDF)

HLA-A03 and response to immune checkpoint blockade in cancer: an epidemiological study

The lancet oncology, 2021-12, Vol.23 (1), p.172-184

2021

Volltextzugriff (PDF)

Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4547-4547

2021

Volltextzugriff (PDF)

DELTA-1: A global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9594-TPS9594

2022

Volltextzugriff (PDF)

First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4072-4072

2019

Volltextzugriff (PDF)

Molecular characteristics of renal cell carcinoma (RCC) risk groups from JAVELIN Renal 101

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.744-744

2020

Volltextzugriff (PDF)

Tremelimumab, a fully human anti-CTLA-4 monoclonal antibody, optimal dosing regimen for patients with unresectable malignant mesothelioma (MM)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3042-3042

2015

Volltextzugriff (PDF)

Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.101-101

2019

Volltextzugriff (PDF)

1 – 25 von 423

Suche als RSS-Feed

Aktive Filter

PublikationsformBücher

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(397)
Mit Volltextzugriff
(359)

Publikationsform

Sprache

Englisch
(423)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(295)
Life Sciences & Biomedicine
(248)
Humans
(187)
Animals
(104)
Female
(103)
Male
(102)
Biological And Medical Sciences
(86)
Medical Sciences
(57)
Adult
(52)
Mice
(51)
Middle Aged
(47)
Immunology
(45)
Fundamental And Applied Biological Sciences. Psychology
(36)
Aged
(32)
Medicine, Research & Experimental
(32)
Research & Experimental Medicine
(32)
Oncology
(30)
Physical Sciences
(30)
Biochemistry & Molecular Biology
(25)
Genetics & Heredity
(24)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations

Use of human tissue to assess the oncogenic activity of melanoma-associated mutations

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

HLA-A03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study

Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma

Hallmarks of Resistance to Immune-Checkpoint Inhibitors

Consistent, Persistent Expression from Modified Retroviral Vectors in Murine Hematopoietic Stem Cells

In vivo Restoration of Laminin 5 β3 Expression and Function in Junctional Epidermolysis Bullosa

Use of TMB and PD-L1 to predict outcomes of checkpoint inhibitor treatment

Sustainable systemic delivery via a single injection of lentivirus into human skin tissue

HLA-A03 and response to immune checkpoint blockade in cancer: an epidemiological study

Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

DELTA-1: A global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma

First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100)

Molecular characteristics of renal cell carcinoma (RCC) risk groups from JAVELIN Renal 101

Tremelimumab, a fully human anti-CTLA-4 monoclonal antibody, optimal dosing regimen for patients with unresectable malignant mesothelioma (MM)

Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

Aktive Filter

Suchergebnisse filtern